NASDAQ: ONCTOncternal Therapeutics Inc Stock
$0.31+0.00 (+0%)
Updated Jun 8, 2023
ONCT Price
$0.31
Fair Value Price
$1.01
Market Cap
$17.97M
52 Week Low
$0.26
52 Week High
$1.41
P/E
-0.36x
P/B
0.34x
P/S
48.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$947.00k
Earnings
-$45.75M
Gross Margin
100%
Operating Margin
-4,831.36%
Profit Margin
-4,831.4%
Debt to Equity
0.11
Operating Cash Flow
-$39M
Beta
0.97
Next Earnings
Aug 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ONCT Overview
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ONCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONCT ($0.31) is undervalued by 69.77% relative to our estimate of its Fair Value price of $1.01 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ONCT ($0.31) is significantly undervalued by 69.77% relative to our estimate of its Fair Value price of $1.01 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ONCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ONCT due diligence checks available for Premium users.
Be the first to know about important ONCT news, forecast changes, insider trades & much more!
ONCT News
Valuation
ONCT fair value
Fair Value of ONCT stock based on Discounted Cash Flow (DCF)
Price
$0.31
Fair Value
$1.01
Undervalued by
69.37%
ONCT ($0.31) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ONCT ($0.31) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ONCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ONCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
11.75x
Market
52.58x
ONCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
5.24x
ONCT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ONCT's financial health
Profit margin
Revenue
$203.0k
Net Income
-$11.5M
Profit Margin
-5,658.6%
ONCT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ONCT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$58.3M
Liabilities
$5.8M
Debt to equity
0.11
ONCT's short-term assets ($57.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCT's short-term assets ($57.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ONCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
-$16.0M
Financing
$1.1M
ONCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONCT vs Biotech Stocks
Oncternal Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.